GME
GameStop Corp.
GME's fundamentals are strong: its operating margin rose 11 points to 14% and it turned 19% of its revenue into free cash flow, though revenue fell 7.7%. At 17x earnings, it's trading less than half its usual 44x. Analysts expect earnings to fall sharply.
VENU
Venu Holding Corporation
There isn't enough reported data to score VENU yet.
GME Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Unavailable |
GME's profitability and cash flow are currently strong, and its revenue is stable. There isn't enough data to rate its balance sheet.
VENU Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
VENU's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
GME PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 17x | $25.62 | — |
| Cheap | 18x | $27.96 | +9.1% |
| Forward | 38x | $25.62 | — |
| Fair | 43x | $66.84 | +161% |
| Expensive | 252x | $388 | +1414% |
Historical ranges are pointers, not guarantees.
GME's PE is in its cheap range at 17x. Analysts expect earnings to fall, which would put today's price at 38x next year's earnings, in its fair range.
VENU PE Valuation
VENU has no meaningful PE right now: it lost money over the past year.
GME Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong decline | |
| Strong decline | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect GME's earnings and revenue to decline, with profitability weakening.
VENU Forward outlook
There aren't enough analyst estimates for VENU to show an outlook.
GME Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.67 | -56% |
| Q3 2026 | $1.54 | +93% |
| Q2 2026 | $1.34 | +153% |
| Q1 2026 | $0.77 | +133% |
| Q4 2025 | $0.89 | +394% |
| Q3 2025 | $0.80 | +515% |
| Q2 2025 | $0.53 | +563% |
| Q1 2025 | $0.33 | +1550% |
| Q4 2024 | $0.18 | +$0.21 |
GME has the edge over VENU in the latest year-over-year earnings comparison.
VENU Earnings Per Share
VENU lost $0.91 per share over the past year, a bigger loss than the year before.
GME Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $790.2M | -19% |
| Q2 2026 | $835.3M | +14% |
| Q1 2026 | $1.1B | -14% |
| Q4 2025 | $821M | -4.6% |
| Q3 2025 | $972.2M | +22% |
| Q2 2025 | $732.4M | -17% |
| Q1 2025 | $1.3B | -28% |
| Q4 2024 | $860.3M | -20% |
GME's revenue has slid since its 2022 peak: $790M last quarter, down 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +13 points |
| Q2 2026 | 17% | +19 points |
| Q1 2026 | 12% | +6 points |
| Q4 2025 | 5% | +8.9 points |
| Q3 2025 | 6.8% | +9.6 points |
| Q2 2025 | -1.5% | +4.3 points |
| Q1 2025 | 6.2% | +3.1 points |
| Q4 2024 | -3.9% | -2.5 points |
GME has the edge over VENU on profitability, with a higher operating margin.
VENU Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $4.8M | +6.9% |
| Q1 2026 | $3.9M | +11% |
| Q4 2025 | $4.5M | +6.1% |
| Q3 2025 | $5.4M | -1.2% |
| Q2 2025 | $4.5M | +7.5% |
| Q1 2025 | $3.5M | -11% |
| Q4 2024 | $4.3M | +9.1% |
| Q3 2024 | $5.5M | +39% |
VENU has the edge over GME on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -320% | -90 points |
| Q1 2026 | -294% | +235 points |
| Q4 2025 | -162% | -12 points |
| Q3 2025 | -185% | -118 points |
| Q2 2025 | -230% | -126 points |
| Q1 2025 | -530% | -201 points |
| Q4 2024 | -150% | -73 points |
| Q3 2024 | -67% | +3 points |
VENU's operating margin was −320% last quarter, down 90 points from the same quarter a year ago.
GME Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $60.7M | -46% |
| Q2 2026 | $332.9M | +76% |
| Q1 2026 | $187.4M | +18% |
| Q4 2025 | $107M | +435% |
| Q3 2025 | $113.3M | +73% |
| Q2 2025 | $189.6M | +$304.3M |
| Q1 2025 | $158.8M | +$177.5M |
| Q4 2024 | $20M | +80% |
GME generated $688M in free cash flow over the past year, up 43% from the year before.
VENU Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$67.9M | -$50.3M |
| Q1 2026 | -$74.4M | -$43.3M |
| Q4 2025 | -$52.4M | -$31.9M |
| Q2 2025 | -$17.6M | -$4.1M |
| Q1 2025 | -$31.1M | -$19.4M |
| Q4 2024 | -$20.4M | -$10.1M |
VENU has burned cash in almost every quarter: −$228M over the past year, against −$83M the year before.
GME Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +300K shares |
| 1 year | +8.4% | +46.1M shares |
| 3 years | +94% | +288M shares |
| 5 years | +104% | +302M shares |
| Available history | +80% | +264M shares |
GME has the edge over VENU on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q1 2020 | $21.8M |
| Q4 2019 | $114M |
VENU Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +26% | +12.4M shares |
| 1 year | +59% | +22M shares |
VENU has 59M diluted shares, up 59% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
GME Net Leverage
VENU Net Leverage
VENU's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
GME Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.9 | Neutral |
| Stochastic | 68.5 | Neutral |
GME's weekly RSI is 60 (neutral) and its Stochastic is 69 (neutral).
VENU Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 27.1 | Oversold |
| Stochastic | 15.7 | Oversold |
VENU's weekly RSI is 27 (oversold) and its Stochastic is 16 (oversold).
GME PE vs Consumer Cyclical Sector
| Metric | GME | Sector median | Relative |
|---|---|---|---|
| PE | 17x | 18x | 7.7% below |
| PE % | 15 | 47 | 32 pts below |
GME is trading at 17x earnings, in line with the Consumer Cyclical sector's median of 18x.
VENU PE vs Consumer Cyclical Sector
VENU has no meaningful PE right now: it lost money over the past year.
GME Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $25.2 | 1.8% above |
| 20 week MA | $22.4 | 15% above |
| 50 week MA | $22.6 | 13% above |
| 100 week MA | $24.0 | 7% above |
| 200 week MA | $21.8 | 17% above |
GME has stronger trend alignment. GME is above 5 of 5 weekly averages versus VENU above 0 of 4.
VENU Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.32 | 5.3% below |
| 20 week MA | $1.76 | 29% below |
| 50 week MA | $3.95 | 68% below |
| 100 week MA | $7.49 | 83% below |
VENU is in a downtrend: it's below all four of its weekly moving averages, and 83% below its 100-week average.
GME Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.48 | $5.04 | +241% |
| 2021 | $5.04 | $38.0 | +655% |
| 2022 | $38.0 | $20.1 | -47% |
| 2023 | $20.1 | $17.5 | -13% |
| 2024 | $17.5 | $32.2 | +84% |
| 2025 | $32.2 | $21.1 | -35% |
| 2026 YTD | $21.1 | $25.6 | +21% |
GME has the edge over VENU on returns for 2026, with the stronger performance.
VENU Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $10.8 | $9.74 | -9.8% |
| 2025 | $9.74 | $8.17 | -16% |
| 2026 YTD | $8.17 | $1.25 | -85% |
VENU has finished every year since 2024 lower, and it's down 85% so far in 2026.